secwatch.observer — SEC 8-K summary
======================================

Issuer:     Royalty Pharma plc (RPRX)
CIK:        0001802768
Form:       8-K
Filed at:   2024-05-29T23:59:59+00:00
Accession:  0001193125-24-149338
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

J&J Phase 3 seltorexant meets all endpoints; Royalty Pharma holds mid-single-digit royalty
--------------------------------------------------------------------------------

- J&J's Phase 3 MDD3001 trial of seltorexant met all primary and secondary endpoints in MDD with insomnia.
- Seltorexant is a first-in-class orexin-2 receptor antagonist; no approved therapies exist for MDD with insomnia.
- Royalty Pharma is entitled to a mid-single-digit royalty on worldwide net sales of seltorexant.
- J&J previously estimated non-risk adjusted peak sales potential of $1B–$5B for seltorexant.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1802768/000119312524149338/0001193125-24-149338-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1802768/000119312524149338/d34372d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-149338

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer